Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASCO GI 2021 | Phase II trial of neoadjuvant bevacizumab + modified FOLFOX7 in rectal cancer

Afsaneh Barzi • 18 Jan 2021
ASCO GI 2021
Gastrointestinal Cancer Rectal Cancer Bevacizumab FOLFOX

Afsaneh Barzi, MD, PhD, City of Hope Comprehensive Cancer Center, Duarte, CA, discusses the results of a Phase II trial of neoadjuvant bevacizumab with modified FOLFOX7 in lieu of radiation in patients with stage II and III rectal cancer. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Afsaneh Barzi

2:27
The current state of MRD testing in colorectal cancer
Afsaneh Barzi • 21 Jan 2023
1:14
Clinical applications of liquid biopsies in colorectal cancer
Afsaneh Barzi • 21 Jan 2023
1:18
How can we mitigate health inequalities in colorectal cancer?
Afsaneh Barzi • 21 Jan 2023
2:57
Assessing the rate of ER utilization prior to CRC diagnosis
Afsaneh Barzi • 21 Jan 2023

Related Videos

1:53
Important pathophysiological determinants of elevated cirDNA post-surgery
Alain Thierry • 9 Apr 2024
0:47
Emerging molecular drivers and biomarker targets in gastroesophageal cancers
Tatsuhiro Shibata • 9 Apr 2024
0:52
DRP-104 with durvalumab in fibrolamellar hepatocellular carcinoma
Marina Baretti • 9 Apr 2024
1:06
The emerging role of cancer vaccines in treating liver cancer
Marina Baretti • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals